Zusammenfassung
Aciclovir ist ein Virustatikum zur Behandlung von Herpes simplex (HSV)Infektionen (Typ 1,2), von Varizella-Zoster (VZV)-Infektionen und von bestimmten durch Epstein-Barr-Virusverursachten Erkrankungen (Haarleukoplakie). Zytomegalie-Virus (CMV)Infektionen sprechen auf Aciclovir im allgemeinen nicht an.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Alford CA (1982) Acyclovir treatment of herpes virus infections in immunocompromised humans. An overview. Amer J Med 20: 225–230
Brigden D, Whiteman P (1983) The mechanism of action, pharmacokinetics and toxicity of aciclovir. J of infection 6 (Suppl 1): 3–9
Furmann PA, ST Clair PA, Fyfe JA, Rideout JL, Keller P, Elion GB (1979) Inhibition of herpes simplex virus induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl) guanine and its triphosphate. J Virol 32: 72–77
DDC
Cooney DA, Dalai M, Mitsuya H et al. (1986) Initial studies on the cellular pharmacology of 2’, 3’-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol, 35: 2065–68
Yarchoan R, Pluda JM, Thomas RV et al. (1988) Long-term treatment of AIDS and AIDS-related complex (ARC) with alternating weekly regimen of AZT and 2’, 3’-dideoxycytidine (DDC) I V International Conference on AIDS, Stockholm, Schweden
Yarchoan R, Perno CF, Thomas RV et al. (1988) Phase I studies of 2’, 3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with Zidovudine ( AZT ). Lancet 1: 76–81
Foscarnet
Deray G, Cacoub P, Le Hoang P et al. (1987) Foscamet-induced acute renal failure and effectiveness of haemodialysis. Lancet 2: 216
Helgstrand E, Eriksson B, Johansson NG et al. (1978) Trisodium phosphonoformate, a new antiviral compound. Science 201: 819–821
Sundquist B, Oberg B (1979) Phosphonoformate inhibits reverse transkriptase. J Gen Virol 45: 273–281
Ganciclovir
Field AK, Davies ME, Devitt et al. (1983) 9-([2hydroxy-1-(hydroxy-methyl) ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 80: 4139–4143
Henderly DE, Freeman WR, Causey DM, Rao NA (1987) Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 94: 425–434
Laskin OL, Cederberg DM, Mills J, Eron LI, Mildvan D, Spector SA (1987) Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 83: 201–207
Interferone
Fischl MA, Patrone-Reese J, Dearmas L, Uttamchandani R (1987) Phase I study of the combination of alpha interferons and zidovudine in patients with AIDS-associated Kaposi’s sarcoma. Ann Meeting of the ISIR, Washington, USA, Abstract II - 47: 774
Miles SA, Cortes E, Marcus SG, Carden J, Rudo R, Mitsuyasu RT (1987) A phase II study of beta-interferon given subcutaneously to patients with AIDS related Kaposi’s sarcoma. III International Conference on AIDS, Washington; USA Abstract TP 227
Murphy PM, Lane C, Gallin JI, Fauci AS (1988) Marked disparity in incidence of bacterial infections in patients with the acquired immundeficincy syndrome receiving interleukin-2 or interferon-gamma. Ann Int Med 108: 36–41
Krown SE (1986) Kaposi’s sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha-A and analysis of prognostic factors. Cancer 57, 1662–1665
Volberding PA, Mitsuyasu RT, Golando JP, Speigel RJ (1987) Treatment of Kaposi’s sarcoma with interferon alfa-2b. Cancer 59: 620–625
Pentamidin
Goa KL, Camoli-Richards DM (1987) Pentamidine isethionate: A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in pneumocystis carinii pneumonia. Drugs 33: 242–258
Zidovudin
Creagh-Kirk T, Doi P, Andrews E (1988) Survival experience among patients with AIDS receiving zidovudine. JAMA 260 /20, 3009–3015
Fischl MA, Richman DD, Grieco MH et al. (1987) The efficacy of azidothymidine ( AZT) in the treatments of patients with AIDS and AIDS-related complex. New Eng J of Med 317: 185–191
Furman PA, Fyfe JS, St. Clair MH et al. (1986) Phosphorylation of 3’-azido-3’-deoxythymidine and selective interaction of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 8333–37
Klecker RW, Collins JM, Yarchoan R et al. (1987) Plasma and cerebrospinal fluid pharmacokinetics of 3’-azido-3’-deoxythymidine: a novel pyrimidine analogue with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol and Therap 41: 407–412
Richman DD, Fisch! MA, Grieco MH et al. (1987) The toxicity of azidothymidine ( AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317: 192–197
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Peters, H.D., Staszewski, S. (1991). Arzneistoffprofile. In: L’age-Stehr, J., Helm, E.B., Stiller, N. (eds) AIDS und die Vorstadien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-11094-2_24
Download citation
DOI: https://doi.org/10.1007/978-3-662-11094-2_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-11095-9
Online ISBN: 978-3-662-11094-2
eBook Packages: Springer Book Archive